The Effect of Raloxifene after Discontinuation of Long-Term Alendronate Treatment of Postmenopausal Osteoporosis | Zendy

Dana Michalská | Zendy; J Štěpán | Zendy; Bruce R. Basson | Zendy; Imre Pávó | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Effect of Raloxifene after Discontinuation of Long-Term Alendronate Treatment of Postmenopausal Osteoporosis

Author(s) -

Dana Michalská,

J Štěpán,

Bruce R. Basson,

Imre Pávó

Publication year - 2006

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2004-2212

Subject(s) - medicine , raloxifene , alendronic acid , discontinuation , osteoporosis , bone remodeling , n terminal telopeptide , femoral neck , bone mineral , urology , endocrinology , placebo , surgery , osteocalcin , breast cancer , estrogen receptor , biochemistry , chemistry , alkaline phosphatase , alternative medicine , pathology , cancer , enzyme

The aim of this study was to compare bone mineral density (BMD) and biochemical markers of bone turnover in patients receiving long-term alendronate therapy who continued alendronate, were switched to raloxifene, or discontinued antiresorptive therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research